Immunologic Research

, Volume 66, Issue 2, pp 255–270 | Cite as

Pemphigus group: overview, epidemiology, mortality, and comorbidities

  • Khalaf Kridin


Pemphigus forms a group of rare autoimmune bullous diseases that affect the skin and mucous membranes. This group has a chronic course leading to high morbidity and mortality. It is characterized by the production of pathogenic autoantibodies directed against different proteins of the desmosome, leading histologically to intraepidermal cleavage, and clinically to vesicles and erosions on the epithelium of the mucous membranes and/or the skin. The diagnosis of the subtype of pemphigus is based on clinical features, the level of histologic cleavage, and the identification of the antigens recognized by circulating autoantibodies by immunoserological analyses. The epidemiological features of pemphigus vary considerably in different regions of the world. Observational studies examining comorbidities and associations among patients with pemphigus are scarce and sometimes inconclusive. The prognosis, mortality, and clinical outcomes in pemphigus have undergone dramatic change throughout the years. This review provides a brief overview about the different subtypes of pemphigus: pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, pemphigus herpetiformis, and IgA pemphigus. In addition, it summarizes the most recent understanding of the epidemiology, mortality data, and comorbidities of this group of organ-specific autoimmune diseases.


Pemphigus Pemphigus vulgaris Pemphigus foliaceus Paraneoplastic pemphigus Pemphigus herpetiformis IgA pemphigus Epidemiology Mortality Comorbidities Associations 


Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.


  1. 1.
    Kridin K, Sagi S, Bergman R. Mortality and cause of death in Israeli patients with pemphigus. Acta Derm. Venereol. [Internet]. 2017 [cited 2017 Mar 9];0. Available from:
  2. 2.
    Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the USA. Br J Dermatol. 2016;174:1290–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Tsunoda K, Ota T, Saito M, Hata T, Shimizu A, Ishiko A, et al. Pathogenic relevance of IgG and IgM antibodies against desmoglein 3 in blister formation in pemphigus vulgaris. Am. J. Pathol. [Internet]. 2011 [cited 2016 Feb 17];179:795–806. Available from:
  4. 4.
    Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin. Exp. Dermatol. 2011. p. 703–7.Google Scholar
  5. 5.
    Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29:432–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22:699–704.CrossRefPubMedGoogle Scholar
  7. 7.
    Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005. p. 61–73.Google Scholar
  8. 8.
    Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol Mech Dis [Internet]. 2016;11:175–97. Available from:. Scholar
  9. 9.
    Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994;94:59–67.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ahmed AR, Blose DA. Pemphigus vegetans: Neumann type and Hallopeau type. Int J Dermatol. 1984;23:135–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429–52.PubMedGoogle Scholar
  12. 12.
    Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982;62:491–6.PubMedGoogle Scholar
  13. 13.
    Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38:382–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980;116:1035–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int. J. Dermatol. [Internet]. 1992 [cited 2017 Dec 6];31:42–5. Available from:
  16. 16.
    Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol [Internet]. 1995 [cited 2016 Feb 17];104:302–5. Available from:
  17. 17.
    Mahé A. Pemphigus in Mali: a study of 30 cases. Br J Dermatol. 1996;134:114–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Micali G, Musumeci ML, Nasca MR. Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int J Dermatol. 1998;37:197–200.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980–1995). Int J Dermatol. 2000;39:104–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Tallab T, Joharji H, Bahamdan K, Karkashan E, Mourad M, Ibrahim K. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol. 2001;40:570–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Hahn-Ristic K, Rzany B, Amagai M, Bröcker EB, Zillikens D. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol. 2002;16:68–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004;43:876–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44:470–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Golušin Z, Poljački M, Jovanović M, Duran V, Stojanović S, Rajić N. Some epidemiological features of pemphigus chronicus in South Vojvodina: a 12-year retrospective study [2]. Int. J. Dermatol. 2005. p. 792–3.Google Scholar
  25. 25.
    Uzun S, Durdu M, Akman A, Gunasti S, Uslular C, Memisoglu HR, et al. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. Int. J. Dermatol. [Internet]. 2006 [cited 2016 Feb 17];45:523–8. Available from:
  26. 26.
    Salmanpour R, Shahkar H, Namazi MR, Rahman-Shenas MR. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991-2000). Int. J. Dermatol. [Internet]. 2006 [cited 2017 Dec 2];45:103–5. Available from:
  27. 27.
    Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007;46:356–61.CrossRefPubMedGoogle Scholar
  28. 28.
    V’lckova-Laskoska MT, Laskoski DS, Kamberova S, Caca-Biljanovska N, Volckova N. Epidemiology of pemphigus in Macedonia: a 15-year retrospective study (1990–2004). Int J Dermatol. 2007;46:253–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ [Internet]. 2008;337:160–3. Available from: Google Scholar
  30. 30.
    Kumar KA. Incidence of pemphigus in Thrissur district, south India. Indian J Dermatol Venereol Leprol. 2008;74:349–51.CrossRefPubMedGoogle Scholar
  31. 31.
    Bertram F, Bröcker E-B, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges [Internet]. 2009;7:434–40. Available from: Google Scholar
  32. 32.
    Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br. J Dermatol. 2009;161:861–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in northwestern Romania. Int J Dermatol. 2010;49:768–74.CrossRefPubMedGoogle Scholar
  34. 34.
    Zaraa I, Kerkeni N, Ishak F, Zribi H, El Euch D, Mokni M, et al. Spectrum of autoimmune blistering dermatoses in Tunisia: an 11-year study and a review of the literature. Int. J. Dermatol. [Internet]. 2011 [cited 2016 Feb 17];50:939–44. Available from:
  35. 35.
    Marinovic B, Lipozencic J, Jukic IL. Autoimmune blistering diseases: incidence and treatment in Croatia. Dermatol. Clin. 2011. p. 677–9.Google Scholar
  36. 36.
    Huang Y-H, Kuo C-F, Chen Y-H, Yang Y-W. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. J Invest Dermatol. [Internet]. 2012;132:92–7. Available from: CrossRefGoogle Scholar
  37. 37.
    Bozdag K, Bilgin İ. Epidemiology of pemphigus in the western region of Turkey: retrospective analysis of 87 patients. Cutan Ocul Toxicol [Internet]. 2012;31:280–5. Available from:. Scholar
  38. 38.
    Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J. Am. Acad. Dermatol. [Internet]. 2016 [cited 2016 Oct 14]; Available from:
  39. 39.
    Milinković M V., Janković S, Medenica L, Nikolić M, Reljić V, Popadić S, et al. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. JDDG J. der Dtsch. Dermatologischen Gesellschaft [Internet]. 2016 [cited 2017 Sep 3];14:995–1005. Available from:
  40. 40.
    Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Acta Derm. Venereol. [Internet]. 2017;0. Available from:
  41. 41.
    Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 1991;88:5056–60. Available from: CrossRefGoogle Scholar
  42. 42.
    Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A. 1990;87:7658–62.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Krain LS. Increased frequency of HL-A10 in pemphigus vulgaris. Arch. Dermatol. [Internet]. American Medical Association; 1973 [cited 2016 Feb 17];108:803. Available from:
  44. 44.
    Mobini N, Yunis EJ, Alper CA, Yunis JJ, Delgado JC, Yunis DE, et al. Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pernphigus vulgaris: possible common central Asian ancestral origin. Hum Immunol. 1997;57:62–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol. [Internet]. 2012;132:1798–805. Available from: CrossRefGoogle Scholar
  46. 46.
    Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. [Internet]. 1996;132:203–12. Available from: CrossRefGoogle Scholar
  47. 47.
    Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol. 2009;145:1005–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7:221–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Anhalt GJ. Making sense of antigens and antibodies in pemphigus. J Am Acad Dermatol. 1999;40:763–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–8.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am. 1998. p. 1239–83.Google Scholar
  52. 52.
    Khachemoune A, Guldbakke KK, Ehrsam E. Pemphigus foliaceus: a case report and short review. Cutis [Internet]. 2006 [cited 2017 Nov 24];78:105–10. Available from:
  53. 53.
    Amerian ML, Ahmed AR. Pemphigus erythematosus: Senear-Usher syndrome. Int. J. Dermatol. 1985. p. 16–25.Google Scholar
  54. 54.
    Diaz LA, Sampaio SAP, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (fogo selvagem): II. Current and historic epidemiologic studies. J Invest Dermatol [Internet]. 1989;92:4–12. Available from: CrossRefGoogle Scholar
  55. 55.
    Korman NJ. New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clin. 2001. p. 637–48.Google Scholar
  56. 56.
    Amagai M. Pemphigus. In: Bolognia JL, Jorizzo JL, Schaffer J V, editors. Dermatology. Third. Elsevier; 2012. p. 461–73.Google Scholar
  57. 57.
    Abreau-Velez AM, Hashimoto T, Bollag WB, Arroyave ST, Abreau-Velez CE, Londoeo ML, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003;49:599–608.CrossRefGoogle Scholar
  58. 58.
    Stanley J. Pemphigus. In: Wolff K, Goldsmith LA, Katz SI, et al., editors. Fitzpatrick’s dermatology in general medicine. New York, McGraw-Hill; 2008. p. 459–68.Google Scholar
  59. 59.
    Del Mar Sáez-de-Ocariz M, Vega-Memije ME, Zúñiga J, Salgado N, Ruíz J, Balbuena A, et al. HLA-DRB1*0101 is associated with foliaceous pemphigus in Mexicans. Int. J. Dermatol. 2005. p. 350.Google Scholar
  60. 60.
    De Sena Nogueira Maehara L, De-Souza-Santana FC, Porro AM, Marcos EVC, Ura S, Nolte IM, et al. HLA class II alleles of susceptibility and protection in Brazilian and Dutch pemphigus foliaceus. Br. J. Dermatol. [Internet]. 2017 [cited 2017 Nov 25]; Available from:
  61. 61.
    Lombardi ML, Mercuro O, Ruocco V, Lo Schiavo A, Lombari V, Guerrera V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol [Internet]. 1999;113:107–10. Available from: CrossRefGoogle Scholar
  62. 62.
    Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15:67–73.CrossRefPubMedGoogle Scholar
  63. 63.
    Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989;20:657–69.CrossRefPubMedGoogle Scholar
  64. 64.
    Empinotti JC, Aoki V, Filgueira A, Sampaio SAP, Rivitti EA, Sanches JA, et al. Clinical and serological follow-up studies of endemic pemphigus foliaceus (fogo selvagem) in western Parana, Brazil (2001–2002). Br J Dermatol. 2006;155:446–50.CrossRefPubMedGoogle Scholar
  65. 65.
    Culton DA, Qian Y, Li N, Rubenstein D, Aoki V, Filhio GH, et al. Advances in pemphigus and its endemic pemphigus foliaceus (fogo selvagem) phenotype: a paradigm of human autoimmunity. J Autoimmun. 2008;31:311–24.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, et al. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and chagas disease suggest a possible etiological link to fogo selvagem. J Invest Dermatol. 2004;123:1045–51.CrossRefPubMedGoogle Scholar
  67. 67.
    Qian Y, Clarke SH, Aoki V, Hans-Filhio G, Rivitti EA, Diaz LA. Antigen selection of anti-DSG1 autoantibodies during and before the onset of endemic pemphigus foliaceus. J Invest Dermatol. 2009;129:2823–34.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Aoki V, Rivitti EA, Diaz LA, Cooperative Group on Fogo Selvagem Research. Update on fogo selvagem, an endemic form of pemphigus foliaceus. J. Dermatol. [Internet]. 2015 [cited 2017 Nov 27];42:18–26. Available from:
  69. 69.
    Robledo MA, Prada S, Jaramillo D, Leon W. South American pemphigus foliaceus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986. Br. J Dermatol. 1988;118:737–44.CrossRefPubMedGoogle Scholar
  70. 70.
    Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol. 2009;161:522–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Abida O, Masmoudi A, Rebaï A, Ben Ayed M, Mahfoudh N, Kallel-Sellami M, et al. The familial feature of Tunisian endemic pemphigus foliaceus. Br. J. Dermatol. 2009. p. 951–3.Google Scholar
  72. 72.
    Joly P, Mokhtar I, Gilbert D, Thomine E, Fazza B, Bardi R, et al. Immunoblot and immunoelectronmicroscopic analysis of endemic Tunisian pemphigus. Br J Dermatol. 1999;140:44–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Kallel Sellami M, Ben Ayed M, Mouquet H, Drouot L, Zitouni M, Mokni M, et al. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin Exp Immunol. 2004;137:195–200.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Leshem YA, Katzenelson V, Yosipovitch G, David M, Mimouni D. Autoimmune diseases in patients with pemphigus and their first-degree relatives. Int J Dermatol. 2011;50:827–31.CrossRefPubMedGoogle Scholar
  75. 75.
    Parameswaran A, Attwood K, Sato R, Seiffert-Sinha K, Sinha AA. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. Br J Dermatol. 2015;172:729–38.CrossRefPubMedGoogle Scholar
  76. 76.
    Chiu Y-W, Chen Y-D, Hua T-C, Wu C-H, Liu H-N, Chang Y-T Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan. Eur. J. Dermatol. [Internet]. 2017 [cited 2017 Dec 2];27:375–81. Available from:
  77. 77.
    Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Ulcerative colitis associated with pemphigus: a population-based large-scale study. Scand J Gastroenterol. 2017;52:1360–4.CrossRefPubMedGoogle Scholar
  78. 78.
    Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol. 1994;3:434–7.CrossRefGoogle Scholar
  79. 79.
    Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and psoriasis: a population-based large-scale study. J. Am. Acad. Dermatol. [Internet]. 2017 [cited 2017 Dec 2];77:1174–5. Available from:
  80. 80.
    Lee CW, Ro YS, Kim JH. Concurrent development of pemphigus foliaceus and psoriasis. Int. J. Dermatol. [Internet]. 1985 [cited 2017 Feb 12];24:316–7. Available from:
  81. 81.
    Aghassi D, Dover JS. Pemphigus foliaceus induced by psoralen-UV-A. Arch. Dermatol. [Internet]. 1998 [cited 2017 Feb 12];134:1300–1. Available from:
  82. 82.
    Lee CW, Ro YS. Pemphigus developed on preexisting dermatoses. J. Dermatol. [Internet]. 1994 [cited 2017 Feb 12];21:213–5. Available from:
  83. 83.
    Tomasini D, Cerri A, Cozzani E, Berti E. Development of pemphigus foliaceus in a patient with psoriasis: a simple coincidence? Eur. J. Dermatol. [Internet]. [cited 2017 Feb 12];8:56–9. Available from:
  84. 84.
    Yokoo M, Oka D, Ueki H. Coexistence of psoriasis vulgaris and pemphigus foliaceus. Dermatologica [Internet]. 1989 [cited 2017 Feb 12];179:222–3. Available from:
  85. 85.
    Perez GL, Agger WA, Abellera RM, Dahlberg P. Pemphigus foliaceus coexisting with IgA nephropathy in a patient with psoriasis vulgaris. Int. J. Dermatol. [Internet]. 1995 [cited 2017 Feb 12];34:794–6. Available from:
  86. 86.
    Giomi B, Cardinali C, Pestelli E, Caproni M, Fabbri P. Pemphigus foliaceus developing on pre-existing psoriasis: a supposed pathogenetic linkage. Acta Derm. Venereol. [Internet]. 2004 [cited 2017 Feb 12];84:82–3. Available from:
  87. 87.
    Kurtzman DJB, Christopher M, Lian F, Sligh JE. A blistering response: concurrent psoriasis and pemphigus foliaceus. Am. J. Med. [Internet]. 2015 [cited 2017 Feb 12];128:24–6. Available from:
  88. 88.
    Kwon HH, Kwon IH, Chung JH, Youn, J Il. Pemphigus foliaceus associated with psoriasis during the course of narrow-band UVB therapy: a simple coincidence? Ann. Dermatol. [Internet]. 2011 [cited 2017 Feb 12];23:S281–4. Available from:
  89. 89.
    Panzarella K, Camisa C. Coexistence of superficial pemphigus and psoriasis. Cutis [Internet]. 1996 [cited 2017 Feb 12];57:414–8. Available from:
  90. 90.
    Caldarola G, Carbone A, De Simone C, Pellicano R. Development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine. J. Am. Acad. Dermatol. [Internet]. 2010 [cited 2017 Feb 13];63:356–7. Available from:
  91. 91.
    Fye KH, Tanenbaum L Penicillamine-induced pemphigus vulgaris in psoriatic arthritis. J. Rheumatol. [Internet]. [cited 2017 Feb 12];9:331–2. Available from:
  92. 92.
    Fryer EJ, Lebwohl M Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J. Am. Acad. Dermatol. [Internet]. 1994 [cited 2017 Feb 12];30:651–3. Available from:
  93. 93.
    Reis VM, Toledo RP, Lopez A, Diaz LA, Martins JE. UVB-induced acantholysis in endemic pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J. Am. Acad. Dermatol. [Internet]. 2000 [cited 2017 Feb 12];42:571–6. Available from:
  94. 94.
    Grunwald MH, David M, Feuerman EJ. Coexistence of psoriasis vulgaris and bullous diseases. J. Am. Acad. Dermatol. [Internet]. 1985 [cited 2017 Feb 13];13:224–8. Available from:
  95. 95.
    Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136–41.CrossRefPubMedGoogle Scholar
  96. 96.
    Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J. Invest. Dermatol. [Internet]. 2015 [cited 2017 Apr 14];135:1445–7. Available from:,DanaInfo=.aadBhpxEjlwJn0z+1-s2.0-S0022202X15372419-main.pdf?_tid=48c2b632-211b-11e7-ab18-00000aab0f26&acdnat=1492178852_19abf9717daebe91b688e3cbd8fcbc2e
  97. 97.
    Kridin K, Zelber-Sagi S, Comaneshter D, Batat E, Cohen AD. Pemphigus and hematologic malignancies: a population-based study of 11,859 patients. J. Am. Acad. Dermatol. [Internet]. Elsevier; 2017 [cited 2017 Dec 2];0. Available from:
  98. 98.
    Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Bipolar disorder associated with another autoimmune disease—pemphigus: a population-based study. Can. J. Psychiatry [Internet]. 2017 [cited 2017 Dec 2];70674371774034. Available from:
  99. 99.
    Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study. Epidemiol. Psychiatr. Sci. [Internet]. 2017 [cited 2017 Dec 2];1–8. Available from:
  100. 100.
    Wohl Y, Mashiah J, Kutz A, Hadj-Rabia S, Cohen AD. Pemphigus and depression comorbidity: a case control study. Eur J Dermatology. 2015;25:602–5.Google Scholar
  101. 101.
    Kumar V, Mattoo SK, Handa S. Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India. Asian J Psychiatr. 2013;6:151–6.CrossRefPubMedGoogle Scholar
  102. 102.
    Arbabi M, Ghodsi Z, Mahdanian A, Noormohammadi N, Shalileh K, Darvish F, et al. Mental health in patients with pemphigus: an issue to worth consideration. Indian J. Dermatol. [Internet]. Medknow Publications; 2011 [cited 2017 Apr 30];56:541–5. Available from:
  103. 103.
    Tabolli S, Mozzetta A, Antinone V, Alfani S, Cianchini G, Abeni D. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the medical outcomes study 36-item short form health survey questionnaire. Br. J. Dermatol. [Internet]. 2008;158:1029–34. Available from:
  104. 104.
    Tabolli S, Pagliarello C, Paradisi A, Cianchini G, Giannantoni P, Abeni D. Burden of disease during quiescent periods in patients with pemphigus. Br J Dermatol. 2014;170:1087–91.CrossRefPubMedGoogle Scholar
  105. 105.
    Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and neurologic diseases. JAMA Dermatol. 2018.
  106. 106.
    Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. 2017;176:87–99.CrossRefPubMedGoogle Scholar
  107. 107.
    Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol [Internet]. 2010;146:1126–31. Available from: file://o/Referenzmanager/Immunglobulin.PDFs/Wohl2010.pdfGoogle Scholar
  108. 108.
    Tee S-I. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate. Arch. Dermatol. [Internet]. 2012;148:307. Available from:
  109. 109.
    Harman M, Uçmak F, Akpolat V, Uçmak D. The frequency of osteoporosis in patients with pemphigus vulgaris on treatment. Indian J. Dermatology, Venereol. Leprol. [Internet]. 2013 [cited 2017 Dec 10];79:211. Available from:
  110. 110.
    Anhalt GJ, Kim S, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. N Engl J Med [Internet]. 1990;323:1729–35. Available from:. Scholar
  111. 111.
    Anhalt GJ. Paraneoplastic pemphigus. J. Investig. Dermatology Symp. Proc. 2004. p. 29–33.Google Scholar
  112. 112.
    Kim SC, Kwon Y, Do LIJ, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol. 1997;109:365–9.CrossRefPubMedGoogle Scholar
  113. 113.
    Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. 1998;111:308–13.CrossRefPubMedGoogle Scholar
  114. 114.
    Schepens I, Jaunin F, Begre N, Läderach U, Marcus K, Hashimoto T, et al. The protease inhibitor alpha-2-macroglobuline-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One. 2010;5(8).Google Scholar
  115. 115.
    Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. JDDG J der Dtsch Dermatologischen Gesellschaft [Internet]. 2010;8:598–605. Available from:. Scholar
  116. 116.
    Wieczorek M, Czernik A. Paraneoplastic pemphigus: a short review. Clin Cosmet Investig Dermatol. 2016;9:291–5.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, et al. Paraneoplastic pemphigus in children and adolescents. Br. J. Dermatol. [Internet]. 2002 [cited 2017 Nov 21];147:725–32. Available from:
  118. 118.
    Leger S, Picard D, Ingen-Housz-Oro S, Arnault J-P, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol [Internet]. 2012;148:1165. Available from:. Scholar
  119. 119.
    Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMedGoogle Scholar
  120. 120.
    Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J. Autoimmun. [Internet]. 2003 [cited 2017 Nov 21];20:91–5. Available from:
  121. 121.
    Liu Q, Bu DF, Li D, Zhu XJ. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol. 2008;158:587–91.CrossRefPubMedGoogle Scholar
  122. 122.
    Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004. p. 553–62.Google Scholar
  123. 123.
    Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.CrossRefPubMedGoogle Scholar
  124. 124.
    Anhalt GJ. Paraneoplastic pemphigus. J. Investig. Dermatology Symp. Proc. [Internet]. 2004 [cited 2017 Nov 22];9:29–33. Available from:
  125. 125.
    Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMedGoogle Scholar
  126. 126.
    Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int. J. Dermatol. 2011. p. 905–14.Google Scholar
  127. 127.
    Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA [Internet]. 1992;267:1500–2. Available from:
  128. 128.
    Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009. p. 129–33.Google Scholar
  129. 129.
    Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol. 2003;149:1143–51.CrossRefPubMedGoogle Scholar
  130. 130.
    Tsuchisaka A, Numata S, Teye K, Natsuaki Y, Kawakami T, Takeda Y, et al. Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients. J Invest Dermatol. 2016;136:399–408.CrossRefPubMedGoogle Scholar
  131. 131.
    Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975;14:353–9.CrossRefPubMedGoogle Scholar
  132. 132.
    Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014;70:780–7.CrossRefPubMedGoogle Scholar
  133. 133.
    Porro AM, Caetano de LVN, Maehara de LSN, dos Enokihara MMS. Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An. Bras. Dermatol. 2014. p. 96–106.Google Scholar
  134. 134.
    Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J. Am. Acad. Dermatol. 1999. p. 649–71.Google Scholar
  135. 135.
    Hocar O, Ait Sab I, Akhdari N, Hakkou M, Amal S. A case of pemphigus herpetiformis in a 12-year-old male. Int Sch Res Netw Pediatr. 2011;2011:1–4.Google Scholar
  136. 136.
    Leithauser LA, Mutasim DF. A case of pemphigus herpetiformis occurring in a 9-year-old boy. Pediatr Dermatol. 2013;30:760–2.CrossRefPubMedGoogle Scholar
  137. 137.
    Moutran R, Maatouk I, Stephan F, Halaby E, Abadjian G, Tomb R. Letter: Pemphigus herpetiformis of age of onset at 6 years. Dermatol Online J. 2011;17Google Scholar
  138. 138.
    Maciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity? Int J Dermatol. 1987;26:571–7.CrossRefPubMedGoogle Scholar
  139. 139.
    Santi CG, Maruta CW, Aoki V, Sotto MN, Rivitti EA, Diaz LA. Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. J Am Acad Dermatol. 1996;34:40–6.CrossRefPubMedGoogle Scholar
  140. 140.
    Morini JP, Jomaa B, Gorgi Y, Saguem MH, Nouira R, Roujeau JC, et al. Pemphigus foliaceus in young women. An endemic focus in the Sousse area of Tunisia. Arch Dermatol [Internet]. 1993;129:69–73. Available from: CrossRefGoogle Scholar
  141. 141.
    Laws PM, Heelan K, Al-Mohammedi F, Walsh S, Shear NH. Pemphigus herpetiformis: a case series and review of the literature. Int J Dermatol. 2015;54:1014–22.CrossRefPubMedGoogle Scholar
  142. 142.
    Muramatsu T, Iida T, Honoki K, Nakatani C, Hatoko M, Shirai T, et al. Pemphigus vulgaris preceded by herpetiform-like skin lesions with negative immunofluorescence findings. J Dermatol [Internet]. 1999;26:154–9. Available from: CrossRefGoogle Scholar
  143. 143.
    Lebeau S, Müller R, Masouyé I, Hertl M, Borradori L. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol. 2010;35:366–72.CrossRefPubMedGoogle Scholar
  144. 144.
    Palleschi GM, Giomi B. Herpetiformis pemphigus and lung carcinoma: a case of paraneoplastic pemphigus. Acta Derm. Venereol. 2002. p. 304–5.Google Scholar
  145. 145.
    Prado R, Brice SL, Fukuda S, Hashimoto T, Fujita M. Paraneoplastic pemphigus herpetiformis with IgG antibodies to desmoglein 3 and without mucosal lesions. Arch Dermatol [Internet]. 2011;147:67. Available from:. Scholar
  146. 146.
    Arranz D, Corral M, Prats I, López-Ayala E, Castillo C, Vidaurrázaga C, et al. Herpetiform pemphigus associated with esophageal carcinoma. Actas Dermosifiliogr. 2005. p. 119–21.Google Scholar
  147. 147.
    Marzano A V, Tourlaki A, Cozzani E, Gianotti R, Caputo R. Pemphigus herpetiformis associated with prostate cancer. J. Eur. Acad. Dermatol. Venereol. [Internet]. 2007 [cited 2017 Nov 20];21:696–8. Available from:
  148. 148.
    Lu Y, Zhang M. Pemphigus herpetiformis in a patient with well-differentiated cutaneous angiosarcoma: case report and review of the published work. J. Dermatol. [Internet]. 2012 [cited 2017 Nov 20];39:89–91. Available from:
  149. 149.
    Sanchez-Palacios C, Chan LS. Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. 2004;31:346–9.CrossRefPubMedGoogle Scholar
  150. 150.
    Morita E, Amagai M, Tanaka T, Horiuchi K, Mizuno H, Yamamoto S. A case of herpetiform pemphigus coexisting with psoriasis vulgaris [6]. Br. J. Dermatol. 1999. p. 754–5.Google Scholar
  151. 151.
    Marinović B, Basta-Juzbašić A, Bukvić-Mokos Z, Ľeović R, Lončrić D. Coexistence of pemphigus herpetiformis and systemic lupus erythematosus. J Eur Acad Dermatology Venereol. 2003;17:316–9.CrossRefGoogle Scholar
  152. 152.
    Shimizu K, Hashimoto T, Wang N, Watanabe K, Ohata Y, Kikuchi A, et al. A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Dermatology [Internet]. 1996 [cited 2017 Nov 20];192:179–82. Available from:
  153. 153.
    Bull RH, Fallowfield ME, Marsden RA. Autoimmune blistering diseases associated with HIV infection. Clin Exp Dermatol. 1994;19:47–50.CrossRefPubMedGoogle Scholar
  154. 154.
    Abe T, Kouno M, Yamamoto N, Mori O, Hashimoto T, Amagai M. A case of D-penicillamine induced herpetiform pemphigus. Nishinihon J Dermatol. 2003;65:126–9.CrossRefGoogle Scholar
  155. 155.
    Weltfriend S, Ingber A, David M, Sandbank M. Pemphigus herpetiformis following D-penicillamine in a patient with HLA B8. Hautarzt. [Internet]. 1988 [cited 2017 Nov 20];39:587–8. Available from:
  156. 156.
    Verdier-Sevrain S, Joly P, Thomine E, Belanyi P, Gilbert D, Tron F, et al. Thiopronine-induced herpetiform pemphigus: report of a case studied by immunoelectron microscopy and immunoblot analysis. Br. J. Dermatol. [Internet]. 1994 [cited 2017 Nov 20];130:238–40. Available from:
  157. 157.
    Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, et al. IgA pemphigus. Clin Dermatol. 2011;29:437–42.CrossRefPubMedGoogle Scholar
  158. 158.
    Geller S, Gat A, Zeeli T, Hafner A, Eming R, Hertl M, et al. The expanding spectrum of IgA pemphigus: a case report and review of the literature. Br. J. Dermatol. 2014. p. 650–6.Google Scholar
  159. 159.
    Hodak E, David M, Ingber A, Rotem A, Hazaz B, Shamai-lubovitz O, et al. The clinical and histopathological spectrum of IgA-pemphigus—report of two cases. Clin Exp Dermatol. 1990;15:433–7.CrossRefPubMedGoogle Scholar
  160. 160.
    Hashimoto T, Kiyokawa C, Mori O, Miyasato M, Chidgey MAJ, Garrod DR, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J. Invest. Dermatol. 1997;109:127–31.CrossRefPubMedGoogle Scholar
  161. 161.
    Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol. 2004;29:62–6.CrossRefPubMedGoogle Scholar
  162. 162.
    Tajima M, Mitsuhashi Y, Irisawa R, Amagai M, Hashimoto T, Tsuboi R. IgA pemphigus reacting exclusively to desmoglein 3. Eur. J. Dermatol. [Internet]. [cited 2017 Nov 23];20:626–9. Available from:
  163. 163.
    Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases associations. Clin. Dermatol. [Internet]. 2012 [cited 2017 Sep 3];30:17–33. Available from:
  164. 164.
    Wallach D. Intraepidermal IgA pustulosis. J. Am. Acad. Dermatol. [Internet]. 1992 [cited 2017 Nov 23];27:993–1000. Available from:
  165. 165.
    Kern J, Gehring W, Kreisel W, Hertl M, Technau-Hafsi K, Bruckner-Tuderman L, et al. Overlap of IgA pemphigus and linear IgA dermatosis in a patient with ulcerative colitis: a mere coincidence? Acta Derm. Venereol. [Internet]. 2014 [cited 2017 Jan 7];94:228–30. Available from:
  166. 166.
    Sotiriou MC, Foo CW, Scholes CT, Zone JJ. Immunobullous disease and ulcerative colitis: a case series of six patients. Br. J. Dermatol. [Internet]. 2015 [cited 2017 Dec 2];173:792–6. Available from:
  167. 167.
    Papakonstantinou E, Kapp A, Jonkman MF, Raap U. Intraepidermal neutrophilic dermatosis type of IgA pemphigus with circulating linear IgA disease antibodies associated with ulcerative colitis. J. Eur. Acad. Dermatology Venereol. [Internet]. 2017 [cited 2017 Dec 2]; Available from:
  168. 168.
    Cetkovská P, Komorousová M, Lomicová I. Management of a pemphigus with IgA and IgG antibodies and coexistent lung cancer. Dermatol. Ther. [Internet]. 2014 [cited 2017 Dec 2];27:236–9. Available from:
  169. 169.
    Petropoulou H, Politis G, Panagakis P, Hatziolou E, Aroni K, Kontochristopoulos G. Immunoglobulin A pemphigus associated with immunoglobulin A gammopathy and lung cancer. J. Dermatol. [Internet]. 2008 [cited 2017 Dec 2];35:341–5. Available from:
  170. 170.
    Gonçalves GAP, Brito MMC, Salathiel AM, Ferraz TS, Alves D, Roselino AMF. Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21-year historical series. An Bras Dermatol [Internet]. 2011;86:1109–12. Available from: CrossRefGoogle Scholar
  171. 171.
    Mimouni D, Bar H, Gdalevich M, Katzenelson V, David M. Pemphigus, analysis of 155 patients. J Eur Acad Dermatol Venereol. 2010;24:947–52.CrossRefPubMedGoogle Scholar
  172. 172.
    Celere BS, Vernal S, Brochado, MJF, Segura-Muñoz SI, Roselino AM. Geographical foci and epidemiological changes of pemphigus vulgaris in four decades in Southeastern Brazil. Int. J. Dermatol. 2017. p. 1494–6.Google Scholar
  173. 173.
    Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol. 2016;75:925–30.CrossRefPubMedGoogle Scholar
  174. 174.
    Hahn K, Kippes W, Amagai M, Rzany B, Brocker EB, Zillikens D. Clinical aspects and immunopathology in 48 patients with pemphigus. Hautarzt [Internet]. 2000;51:670–7. Available from: file://o/Referenzmanager/Immunglobulin.PDFs/Hahn2000.pdfGoogle Scholar
  175. 175.
    Amin MN, Islam AZMM. Clinical, histologic and immunologic features of pemphigus in Bangladesh. Int J Dermatol. 2006;45:1317–8.CrossRefPubMedGoogle Scholar
  176. 176.
    Krain LS. Pemphigus: epidemiologic and survival characteristics of 59 patients, 1955–1973. Arch. Dermatol. [Internet]. American Medical Association; 1974 [cited 2017 Dec 3];110:862. Available from:

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyRambam Health Care CampusHaifaIsrael

Personalised recommendations